Table 2 Univariate and multivariate analysis using Cox proportional hazards for the incidence of all-cause death

From: Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis

 

Univariate Analysis

Model 1

Model 2

Model 3

Model 4

HR

95%CI

P value

HR

95%CI

P value

HR

95%CI

P value

HR

95%CI

P value

HR

95%CI

P value

Age

1.04

1.00–1.08

0.044

1.04

1.00–1.08

0.026

1.05

1.01–1.08

0.015

1.05

1.02–1.09

0.006

1.03

0.99–1.07

0.094

Female

1.80

0.85–3.84

0.127

2.01

0.92–4.39

0.081

1.85

0.84–4.04

0.125

2.40

1.08–5.30

0.031

1.93

0.89–4.19

0.097

Stage III-IV

3.80

1.16–12.48

0.028

   

3.38

1.00–11.39

0.049

      

ECOG-PS 1 or more

6.68

2.75–16.20

<0.001

      

8.39

3.26–21.59

<0.001

   

mALBI grade 2 or more

2.06

1.06–4.01

0.032

         

1.79

0.89–3.61

0.104

Blood pressure elevated

0.40

0.20–0.80

0.009

0.41

0.21–0.81

0.011

0.49

0.24–0.97

0.042

0.43

0.22–0.87

0.019

0.42

0.21–0.83

0.013

  1. CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, HR hazard ratio; mALBI, modified albumin-bilirubin